Cellectis (CLLS) Net Income towards Common Stockholders Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -426.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -426.90% |
| Dec 31, 2025 | -91.81% |
| Sep 30, 2025 | 308.56% |
| Dec 31, 2024 | -34.81% |
| Sep 30, 2024 | 126.53% |
| Dec 31, 2023 | -1,343.97% |
| Sep 30, 2023 | -205.75% |
| Jun 30, 2023 | -2,472.62% |
| Dec 31, 2022 | 64.15% |
| Sep 30, 2022 | 86.50% |
| Jun 30, 2022 | 98.82% |
| Dec 31, 2021 | 79.39% |
| Sep 30, 2021 | -44.34% |
| Jun 30, 2021 | -13.47% |
| Dec 31, 2020 | -1.74% |
| Sep 30, 2020 | -10.14% |
| Jun 30, 2020 | 5.96% |
| Mar 31, 2020 | 162.34% |
| Dec 31, 2019 | -31.54% |
| Sep 30, 2019 | 7.79% |
| Jun 30, 2019 | -61.90% |
| Mar 31, 2019 | 7.16% |
| Dec 31, 2018 | -5.41% |
| Sep 30, 2018 | -12.45% |
| Jun 30, 2018 | -9.38% |
| Mar 31, 2018 | -26.03% |
| Dec 31, 2017 | -36.60% |
| Sep 30, 2017 | -99.29% |
| Jun 30, 2017 | -75.24% |
| Mar 31, 2017 | 12.23% |
| Jun 30, 2016 | 15.54% |
| Mar 31, 2016 | -459.99% |